Diffuse Lung Disease
-
Radiologists, pulmonologists to discuss identification of interstitial lung abnormalities
Joe Mammarappallil, MD, PhD, will chair a Monday afternoon session on the recognition and risk stratification of ILAs, including how to differentiate imaging red herrings from findings that point toward progressive fibrosis.
-
90th anniversary sessions to reflect on past, present, and future of field
Nichole T. Tanner, MD, MSCR, FCCP, and five other CHEST experts will chair special sessions about 90 years of progress in mechanical ventilation, TB, lung cancer, diffuse lung disease, respiratory vaccines, and asthma.
-
Speakers to discuss crucial distinctions of familial, sporadic ILDs
Mary Beth Scholand, MD, FCCP, will serve as co-chair of a Sunday afternoon session on current practices in assessing familial and sporadic ILD patients with telomere measurements and genetic testing.
-
CHEST grant recipient reflects on completed project in streamlining ILD diagnoses
With her project complete, Kavitha Selvan, MD, shares how the quality improvement grant from CHEST through the Bridging Specialties®: Timely Diagnosis for ILD program has impacted patient care, affected providers, and supported her growth as a clinician.
-
Study identifies key environmental exposures associated with risk of interstitial lung disease
Bradford C. Bemiss, MD, MSc, said the findings underscore the importance of asking patients about potential workplace inhalation exposures.
-
Nerandomilast opens the door for potential monotherapy, add-on therapy for pulmonary fibrosis
Positive results from the FIBRONEER trials of nerandomilast in IPF and PPF have sent the phosphodiesterase 4B inhibitor to the FDA for marketing approval. If approved, nerandomilast would be the first new antifibrotic agent for ILD in more than a decade.
-
New data confirms ILD as lung cancer risk factor
Bradford C. Bemiss, MD, and Claudia Henschke, PhD, MD, said the study clearly shows patients with interstitial lung disease have an increased risk of lung cancer.
-
Admilparant phase 2 results raise hopes for combination treatment in pulmonary fibrosis
Fernando Martinez, MD, FCCP, said he expects the treatment options for fibrotic lung disease will soon become more complex—in a good way—as more effective therapies become available.
-
Newest Bridging Specialties program focuses on team-based care in PH-ILD
The Bridging Specialties®: Timely Diagnosis for PH-ILD program encourages collaboration across disciplines and provides assets designed for practical use.
-
Top-line results from FIBRONEER-ILD point to possible third agent for interstitial lung disease
If the data prove accurate, Barry Shea, MD, said nerandomilast could become the first new treatment for lung fibrosis in more than a decade.
